Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Vγ9Vδ2 T cell receptor (TCR) is a semi-invariant γδ TCR predominantly found on the major subset of human peripheral blood γδ T cells, known as Vγ9Vδ2 T cells. This receptor recognizes small non-peptidic phosphoantigens (pAgs), such as isopentenyl pyrophosphate (IPP) and microbial HMB-PP, which accumulate in infected or transformed cells, presented by butyrophilin molecules like BTN3A1. Upon activation, Vγ9Vδ2 T cells exhibit cytotoxic activity, produce cytokines, and can function as antigen-presenting cells, bridging innate and adaptive immunity. They play a role in cancer immunotherapy and defense against infections. Activity is modulated by NK-cell receptors, chemokine receptors and checkpoint pathways.
Activation of Vγ9Vδ2 T cells via phosphoantigen recognition and subsequent cytotoxic activity and cytokine release.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vγ9Vδ2 T cell receptor (Vγ9Vδ2 TCR).